rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

IN8bio, Inc.

INAB · Nasdaq

Health CareBiotechnologyNot moving yet

INAB stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 26.3% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
21 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders21+4 on the quarter
New · exited5 · 1
Reported value$6.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Stonepine Capital Management, LLCadded · filed 14 Aug 20261,624,562$2.3M+961,150+144.9%
Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026944,319$1.3M00.0%
FRANKLIN RESOURCES INCunchanged · filed 13 Aug 2026914,531$1.3M00.0%
683 Capital Management, LLCunchanged · filed 14 Aug 2026724,637$1.0M00.0%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 202688,865$127K+88,865
BIOS Capital Management, LPreduced · filed 14 Aug 202680,957$114K-86,848−51.8%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202672,550$102K-13,689−15.9%
CITADEL ADVISORS LLCnew · filed 14 Aug 202663,055$89K+63,055
OPPENHEIMER & CO INCadded · filed 3 Aug 202663,042$89K+39,009+162.3%
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 202643,570$62K+43,570
31 Mar 2023 – 30 Jun 2026
132128Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Emily Fairbairn Company insiderDirector · last 27 May 20260 · 0
Corinne Epperly Company insiderDirector · last 9 May 20260 · 0
Jeremy R. Graff Company insiderDirector · last 9 May 20261 · 0
Kate Rochlin Company insiderPresident and COO · last 9 May 20261 · 0
Lawrence Lamb Company insiderEVP and CSO · last 9 May 20261 · 0
Luba Greenwood Company insiderDirector · last 9 May 20261 · 0
Patrick McCall Company insiderCHIEF FINANCIAL OFFICER · last 9 May 20262 · 0
Peter C. Brandt Company insiderDirector · last 9 May 20261 · 0
William Tai-Wei Ho Company insiderCEO · last 9 May 20262 · 0
Alan S. Roemer Company insiderDirector · last 22 Dec 20251 · 0
Bios Fund Ii, Lp Company insider10% owner · last 2 May 20251 · 0
Bios Fund Iii Nt, Lp Company insider10% owner · last 2 May 20250 · 0

Same industry

IOVA Iovance BiotherapeuticsLeading+124%
MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
ABCL AbCellera BiologicsLeading+50%
HALO Halozyme TherapeuticsLeading+47%
XNCR XencorLeading+44%
XERS Xeris Biopharma HoldingsLeading+42%
CPIX Cumberland PharmaceuticalsLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-66.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$27.3M

Analyst forecasts

No analyst forecasts yet.